top of page

Emily Dworkin

PharmD, BCOP

Rotations

Outpatient Adult Leukemia, AYA cancer clinic

Education

PharmD: University of Iowa

Residency Training

PGY1: University of Wisconsin Health
PGY2 Oncology/Hematology: University of Wisconsin Health

Emily Dworkin

Practice Interests

Acute Leukemia, Adolescent and Young Adult (AYA) Cancers, Quality Improvement and Pharmacy Practice Advancement

Professional Affiliation

  • Hematology/Oncology Pharmacy Association (HOPA)

  • American Society of Health-System Pharmacists (ASHP)

Recent Publications

  • Bauer J, Craven A, Dworkin E, Drazer M. Implications of off-label prescribing of novel therapies in acute myeloid leukemia. Abstract. The Hematology/Oncology Pharmacy Association Annual Conference, Phoenix, AZ. March 2023.

  • Cahill K, Alban J, Mortel M, Dworkin E, Kosuri S, Duvall A, Liu H, Bishop M, Larson R, Stock W. Low incidence of veno-occlusive disease in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab followed by allogeneic stem cell transplant. The American Society of Clinical Oncology Annual Meeting, June 2021. J Clin Onc 39, 2021 (supp 15; abstract e19024).

  • Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152-159.

  • Dworkin E, Hager D. Taking the fear out of feedback: models for success. J Pharm Soc Wis.2016;19(2):22-25.

  • Madero-Marroquin R, Cannova J, Dworkin E, et al. Outcomes for patients with myeloid neoplasms treated with chemotherapy plus venetoclax after prior venetoclax therapy. EJHaem. 2025 Jun 13;6(3):e70078  

  • Gangat N, Elbeih A, Ghosoun N… Dworkin E, et al. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2025 Feb;100(2):260-27  

  • Achar RK, McCormick BJ, Dworkin E, Geramita EM, Im A, Patel AA, Badar T, Shallis RM. Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy. Leuk Res. 2024 Nov;146:107577  

  • Collins J, Duvall A, Dworkin E, Castiel M. A systemic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. J Oncol Pharm Pract. 2024 Oct;30(7):1259-1267  

  • Madero-Marroquin R, Dworkin E, et al. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47 directed therapy. Leuk Lymphoma. Published online March 5, 2024.  

  • Roloff GW, Wen F, Ramsland A… Dworkin E, et al. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 Aug 1;108(8):2234-2239  

  • Dworkin E, Signorelli J. A possible chemotherapy-free era for acute lymphoblastic leukemia? Oncolytics Today. Fall 2022. 38-45.  

  • Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(11):725-733.  

  • Patel AA, Heng J, Dworkin E, Monick S, Derman B, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021;2(3):413-420

Academic and/or National Presentations

  • Optimal intensive induction for older adults with newly diagnosed acute myeloid leukemia. Presented at the Hematology/Oncology Pharmacy Association Annual Conference. Boston, MA. April 2022

  • Checkpoint inhibitors in hematologic malignancies. Recorded Lecture for The Hematology/Oncology Pharmacy Association 2021 BCOP Oncology Pharmacy Updates

  • Advances in targeted therapy for AML: Practical management of BCL-2 inhibitors. Abbvie Sponsored Symposium. Presented at The Hematology/Oncology Pharmacy Association Annual Conference. [Virtual] April 2021

  • Updates in pharmacology: A focus on menin inhibitors and bi-specific antibodies The University of Chicago Annual Updates from ASH 2023. Chicago, IL. March 2024  

  • Debate: Optimal intensive induction for older adults with newly diagnosed acute myeloid leukemia Presented at the Hematology/Oncology Pharmacy Association Annual Conference. Boston, MA. April 2022 [ACPE Accredited]  

  • Checkpoint inhibitors in hematologic malignancies Recorded Lecture for the Hematology/Oncology Pharmacy Association 2021 BCOP Oncology Pharmacy Updates Course [BCOP and ACPE Accredited]  

  • Advances in targeted therapy for AML: Practical management of BCL-2 inhibitors Abbvie Sponsored Symposium. Presented at The Hematology/Oncology Pharmacy Association Annual Conference. [Virtual] April 2021

Current Research

  • Off label prescribing of novel agents in acute myeloid leukemia, with Jordan Baur, PharmD

  • The impact of a pharmacist driven protocol for management of 6MP and oral MTX during AML maintenance therapy with Kaitlin Kelly, PharmD, BCOP

bottom of page